MA33803B1 - Inhibiteur de bromodomaine de benzodiazépine - Google Patents

Inhibiteur de bromodomaine de benzodiazépine

Info

Publication number
MA33803B1
MA33803B1 MA34934A MA34934A MA33803B1 MA 33803 B1 MA33803 B1 MA 33803B1 MA 34934 A MA34934 A MA 34934A MA 34934 A MA34934 A MA 34934A MA 33803 B1 MA33803 B1 MA 33803B1
Authority
MA
Morocco
Prior art keywords
benzodiazepine
bromodomaine
inhibitor
compound
formula
Prior art date
Application number
MA34934A
Other languages
Arabic (ar)
English (en)
Inventor
Romain Luc Marie Gosmini
Olivier Mirguet
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42667965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33803(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0919433A external-priority patent/GB0919433D0/en
Priority claimed from GBGB1010509.6A external-priority patent/GB201010509D0/en
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA33803B1 publication Critical patent/MA33803B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un composé benzodiazépine de formule (I), des procédés pour sa préparation, des compositions pharmaceutiques contenant un tel composé et son utilisation en thérapie.
MA34934A 2009-11-05 2012-06-04 Inhibiteur de bromodomaine de benzodiazépine MA33803B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0919433A GB0919433D0 (en) 2009-11-05 2009-11-05 Novel compounds
GBGB1010509.6A GB201010509D0 (en) 2010-06-22 2010-06-22 Novel compounds
PCT/EP2010/061518 WO2011054553A1 (fr) 2009-11-05 2010-08-06 Inhibiteur de bromodomaine de benzodiazépine

Publications (1)

Publication Number Publication Date
MA33803B1 true MA33803B1 (fr) 2012-12-03

Family

ID=42667965

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34934A MA33803B1 (fr) 2009-11-05 2012-06-04 Inhibiteur de bromodomaine de benzodiazépine

Country Status (32)

Country Link
US (3) US9023842B2 (fr)
EP (3) EP2496580B1 (fr)
JP (1) JP5524343B2 (fr)
KR (1) KR101424989B1 (fr)
CN (1) CN102762569B (fr)
AU (1) AU2010314395B2 (fr)
BR (1) BR112012010706A2 (fr)
CA (1) CA2779355C (fr)
CL (1) CL2012001178A1 (fr)
CO (1) CO6540003A2 (fr)
CR (1) CR20120283A (fr)
CY (2) CY1114988T1 (fr)
DK (2) DK2496580T3 (fr)
DO (1) DOP2012000114A (fr)
EA (1) EA020390B1 (fr)
ES (3) ES2446647T3 (fr)
HK (3) HK1191012A1 (fr)
HR (2) HRP20140107T1 (fr)
HU (1) HUE026421T2 (fr)
IL (2) IL219090A0 (fr)
MA (1) MA33803B1 (fr)
ME (1) ME02360B (fr)
MX (1) MX2012005295A (fr)
MY (1) MY160456A (fr)
NZ (1) NZ599258A (fr)
PE (1) PE20121181A1 (fr)
PL (2) PL2722334T3 (fr)
PT (2) PT2496580E (fr)
RS (2) RS54592B1 (fr)
SI (2) SI2722334T1 (fr)
SM (2) SMT201400024B (fr)
WO (1) WO2011054553A1 (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
MX341212B (es) * 2009-11-05 2016-08-11 Glaxosmithkline Llc * Inhibidor de bromodominio de benzodiazepina.
AU2011252799B2 (en) 2010-05-14 2015-05-14 Cold Spring Harbor Laboratory Compositions and methods for treating leukemia
JP6022442B2 (ja) 2010-05-14 2016-11-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 男性用避妊組成物および使用方法
BR122014024883A2 (pt) 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. Compostos no tratamento de neoplasia
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (fr) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Inhibiteurs à bromodomaine et leurs utilisations
WO2013027168A1 (fr) 2011-08-22 2013-02-28 Pfizer Inc. Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (fr) 2011-12-30 2013-07-04 Abbott Laboratories Inhibiteurs de bromodomaine
CA2870931A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Derives d'iso-indolone
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
KR20150023722A (ko) 2012-06-12 2015-03-05 애브비 인코포레이티드 피리디논 및 피리다지논 유도체
EP2884983B1 (fr) 2012-08-16 2017-10-04 GlaxoSmithKline LLC Benzodiazepines pour traiter le carcinome pulmonaire à petites cellules
US9890147B2 (en) 2012-08-16 2018-02-13 Bayer Pharma Aktiengesellshaft 2,3-benzodiazepines
WO2014048945A1 (fr) 2012-09-28 2014-04-03 Bayer Pharma Aktiengesellschaft 5-aryl-triazolo-azepines inhibant la protéine bet
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) * 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
EP2935253B1 (fr) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Nouveaux composés hétérocycliques en tant qu'inhibiteurs de bromodomaine
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CA2902225A1 (fr) * 2013-02-28 2014-09-04 Washington University Methodes de traitement de maladies et d'infections par le cytomegalovirus humain au moyen d'inhibiteurs de bromodomaines
EP2970262A1 (fr) 2013-03-11 2016-01-20 AbbVie Inc. Inhibiteurs de bromodomaine
CA2904049A1 (fr) 2013-03-11 2014-10-09 Abbvie Inc. Inhibiteurs de bromodomaines tetracycliques de fusion
WO2014159392A1 (fr) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Réactifs de liaison à des bromodomaines et leurs utilisations
US9695179B2 (en) * 2013-03-14 2017-07-04 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
CN105189515B (zh) * 2013-03-14 2018-07-03 葛兰素史克知识产权第二有限公司 作为溴结构域抑制剂的呋喃并吡啶类
SG11201506924YA (en) 2013-03-15 2015-09-29 Incyte Corp Tricyclic heterocycles as bet protein inhibitors
EP2792355A1 (fr) 2013-04-17 2014-10-22 Albert-Ludwigs-Universität Freiburg Composés destinés à être utilisés comme inhibiteurs de bromodomaine
AU2014256750B2 (en) 2013-04-26 2018-08-23 Beigene, Ltd. Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
CN105492439B (zh) 2013-06-21 2019-11-22 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的取代的双环化合物
KR102307566B1 (ko) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
AR096758A1 (es) * 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
JP2016523964A (ja) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
EP3027604B1 (fr) 2013-07-31 2019-02-20 Zenith Epigenetics Ltd. Nouvelles quinazolones en tant qu'inhibiteurs de bromodomaine
US9428513B2 (en) 2013-11-07 2016-08-30 Boehringer Ingelheim International Gmbh Triazolopyrazine
JP6637884B2 (ja) 2013-11-08 2020-01-29 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
WO2015081203A1 (fr) 2013-11-26 2015-06-04 Incyte Corporation Hétérocycles bicycliques servant d'inhibiteurs des protéines bet
WO2015081189A1 (fr) 2013-11-26 2015-06-04 Incyte Corporation Hétérocycles bicycliques servant d'inhibiteurs des protéines bet
GB201320994D0 (en) * 2013-11-28 2014-01-15 Univ Dundee Enzyme function probes
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
RU2016134941A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диазепана и их применения
EP3099677A4 (fr) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Dérivés de diaminopyrimidine benzènesulfone et leurs utilisations
WO2015117087A1 (fr) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Utilisations des dérivés de diazépane
WO2015120476A1 (fr) * 2014-02-10 2015-08-13 Salk Institute For Biological Studies Augmentation du stockage de vitamine a, de vitamine d et/ou de lipides
CN106459056A (zh) 2014-02-10 2017-02-22 康塞特医药品公司 经取代的三唑苯二氮卓
WO2015121230A1 (fr) * 2014-02-14 2015-08-20 Bayer Pharma Aktiengesellschaft 2,3-benzodiazépines substituées en position 9
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
ES2751642T3 (es) 2014-04-09 2020-04-01 Kainos Medicine Inc Compuestos inhibidores de bromodominios y composición farmacéutica que los comprende para prevenir o tratar un cáncer
EA039678B1 (ru) 2014-04-23 2022-02-24 Инсайт Корпорейшн 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET
CA2952830C (fr) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Formes cristallines de l'acetamide 2-((4s)-6- (4-chlorophenyl)-1-methyl-4 h-benzo [c] isoxazolo [4s5-e] azepin-4-yle)
NO2719005T3 (fr) 2014-07-28 2018-01-20
SG10201900631TA (en) * 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
BR112017002369A2 (pt) 2014-08-08 2017-12-05 Dana Farber Cancer Inst Inc derivados de diazepana e usos dos mesmos
CA2955077A1 (fr) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Derives de dihydropteridinone et leurs utilisations
EP3194406B8 (fr) 2014-09-15 2021-03-31 Incyte Corporation Composes triheterocycliques a utilisation comme inhibiteurs de proteine bet
EP3201199A1 (fr) 2014-10-02 2017-08-09 Glaxosmithkline Intellectual Property (No. 2) Limited Composé
EP3212654B1 (fr) 2014-10-27 2020-04-08 Tensha Therapeutics, Inc. Inhibiteurs de bromodomaine
WO2016087936A1 (fr) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Pyridinones substituées utilisées comme inhibiteurs de bromodomaines
WO2016087942A1 (fr) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Pyridines substituées comme inhibiteurs de bromodomaine
WO2016090219A1 (fr) * 2014-12-05 2016-06-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibiteur de bromodomaines comme adjuvant en immunothérapie anticancéreuse
EP3230277B1 (fr) 2014-12-11 2019-09-18 Zenith Epigenetics Ltd. Hétérocycles substitués à titre d'inhibiteurs de bromodomaines
EP3233846A4 (fr) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibiteurs de bromodomaines
US10259809B2 (en) 2015-02-03 2019-04-16 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP2018520124A (ja) 2015-06-26 2018-07-26 テンシャ セラピューティクス，インコーポレイテッド Ｎｕｔ正中線癌の治療
JP6765622B2 (ja) 2015-07-17 2020-10-07 日本光電工業株式会社 救命支援装置
PE20181086A1 (es) 2015-09-11 2018-07-05 Dana Farber Cancer Inst Inc Acetamida tienotrizolodiazepinas y usos de las mismas
MX2018003031A (es) 2015-09-11 2018-08-01 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas.
CA2999523A1 (fr) * 2015-10-02 2017-04-06 Dana-Farber Cancer Institute, Inc. Polytherapie par inhibiteurs de bromodomaine et blocage de point de controle
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
AU2016361478B2 (en) 2015-11-25 2020-09-10 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
DK3442972T3 (da) 2016-04-15 2020-04-27 Abbvie Inc Bromdomænehæmmere
RS64274B1 (sr) 2016-06-20 2023-07-31 Incyte Corp Kristalni čvrsti oblici bet inhibitora
ES2937307T3 (es) 2016-07-26 2023-03-27 Univ Southern California Inhibición selectiva del bromodominio del BDF1 fúngico
RU2019117356A (ru) 2016-11-10 2020-12-10 Лосинь Фармасьютикал (Шанхай) Ко., Лтд. Азотсодержащее макроциклическое соединение, способ его получения, фармацевтическая композиция и применение
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
CN107759607B (zh) * 2017-11-29 2019-08-23 上海万巷制药有限公司 具有抗肿瘤活性的三氮唑并二氮卓化合物及其制备方法
MX2021006544A (es) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
WO2020191326A1 (fr) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Traitement de la leucémie myéloïde aiguë (aml) après échec du vénétoclax
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2021175432A1 (fr) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Procédé d'administration d'un agent anticancéreux
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
MX2022016454A (es) 2020-06-23 2023-03-06 Genentech Inc Compuestos macrociclicos y metodos de uso de los mismos.
GB202016977D0 (en) 2020-10-26 2020-12-09 In4Derm Ltd Compounds
WO2022116968A1 (fr) 2020-12-01 2022-06-09 成都苑东生物制药股份有限公司 Nouvel inhibiteur de bromodomaine bet n-hétérocyclique, procédé de préparation s'y rapportant et utilisation médicale associée
JP2024523491A (ja) 2021-06-29 2024-06-28 タイ セラピューティクス リミテッド がんの治療に有用なピロロピリドン誘導体
WO2023205251A1 (fr) 2022-04-19 2023-10-26 Nuevolution A/S Composés actifs vis-à-vis de bromodomaines
WO2024018423A1 (fr) 2022-07-21 2024-01-25 Tay Therapeutics Limited Pyrroles et imidazoles utilisés comme inhibiteurs de protéines bet

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3610848A1 (de) * 1986-04-01 1987-10-15 Boehringer Ingelheim Kg Neue 1,4-diazepine
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
EP0638560A4 (fr) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical Medicament utilise pour traiter l'osteoporose et compose de diazepine.
JPH06128257A (ja) 1992-10-13 1994-05-10 Yoshitomi Pharmaceut Ind Ltd ピリドジアゼピン化合物
AU686715B2 (en) 1993-11-22 1998-02-12 Merck & Co., Inc. Tricyclic benzodiazepinyl amide derivatives as amtiarrhythmics
IT1285567B1 (it) 1996-02-21 1998-06-18 Alfa Chem Ital Nuovo processo per la sintesi del nabumetone
BR9710453A (pt) * 1996-06-12 1999-08-17 Japan Tobacco Inc Inhibidor de produ-Æo de citocina composto de triazepina e intermedi rio para o mesmo
KR100338144B1 (ko) 1996-09-13 2002-05-24 가마쿠라 아키오 티에노트리아졸로디아제핀 화합물 및 그의 약제학적 용도
JPH11228576A (ja) * 1997-12-10 1999-08-24 Japan Tobacco Inc アポトーシス抑制剤
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
US7223733B2 (en) 2004-03-31 2007-05-29 National University Of Singapore Modulation of TRIP-Br function and method of treating proliferative disorders
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
JP5159305B2 (ja) 2005-05-30 2013-03-06 田辺三菱製薬株式会社 チエノトリアゾロジアゼピン化合物及びその医薬としての用途
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
EP2239264A4 (fr) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp Agent antitumoral
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds

Also Published As

Publication number Publication date
CO6540003A2 (es) 2012-10-16
ME02360B (fr) 2016-06-20
US20120220573A1 (en) 2012-08-30
IL235983A0 (en) 2015-01-29
JP5524343B2 (ja) 2014-06-18
IL219090A0 (en) 2012-06-28
PT2496580E (pt) 2014-02-21
CL2012001178A1 (es) 2012-10-05
EP2496580B1 (fr) 2013-12-11
EP2722334A1 (fr) 2014-04-23
RS54592B1 (en) 2016-08-31
HRP20140107T1 (hr) 2014-04-25
DOP2012000114A (es) 2012-08-15
HK1175458A1 (en) 2013-07-05
MY160456A (en) 2017-03-15
JP2013510107A (ja) 2013-03-21
EP2722334B1 (fr) 2016-01-13
SMT201400024B (it) 2014-07-07
PT2722334E (pt) 2016-03-11
AU2010314395A1 (en) 2012-05-24
NZ599258A (en) 2014-05-30
EP2496580A1 (fr) 2012-09-12
DK2722334T3 (en) 2016-03-07
MX2012005295A (es) 2012-06-19
PL2722334T3 (pl) 2016-06-30
HRP20160119T1 (hr) 2016-02-26
ES2652304T3 (es) 2018-02-01
US20150210706A1 (en) 2015-07-30
CA2779355C (fr) 2018-01-16
KR101424989B1 (ko) 2014-07-31
EP3037423B1 (fr) 2017-09-20
DK2496580T3 (da) 2014-02-24
HK1191012A1 (zh) 2014-07-18
ES2446647T3 (es) 2014-03-10
US9023842B2 (en) 2015-05-05
EP3037423A1 (fr) 2016-06-29
CY1117479T1 (el) 2017-04-26
SI2496580T1 (sl) 2014-02-28
EA020390B1 (ru) 2014-10-30
CA2779355A1 (fr) 2011-05-12
CN102762569A (zh) 2012-10-31
PL2496580T3 (pl) 2014-06-30
CN102762569B (zh) 2015-04-01
HUE026421T2 (en) 2016-05-30
CY1114988T1 (el) 2016-12-14
HK1220188A1 (zh) 2017-04-28
SMT201600081B (it) 2016-04-29
BR112012010706A2 (pt) 2016-03-29
IL235983B (en) 2018-01-31
KR20120099250A (ko) 2012-09-07
PE20121181A1 (es) 2012-09-13
WO2011054553A1 (fr) 2011-05-12
RS53179B (en) 2014-06-30
US20170197972A1 (en) 2017-07-13
SI2722334T1 (sl) 2016-03-31
ES2563057T3 (es) 2016-03-10
EA201290183A1 (ru) 2012-12-28
CR20120283A (es) 2012-08-14
AU2010314395B2 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MY153915A (en) Organic compounds
EA201170832A1 (ru) Пуриновые соединения
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA201170772A1 (ru) Органические соединения
MX2009000884A (es) Derivados de piridizinona.
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
IN2012DN00971A (fr)
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201270590A1 (ru) Ингибиторы акт
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань